Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) ...Middle East

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1 Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P

Read More Details
Finally We wish PressBee provided you with enough information of ( Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) )

Also on site :

• Bodies of two Israeli-American hostages recovered from Gaza in joint military operation
• Second interview with AUC professor Bahgat Korany discusses Suez Canal, GERD concerns & global politics
• Greta Thunberg DEPORTED by Israel after ‘Freedom Flotilla’ Gaza stunt as she’s loaded on plane & sent to France